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A Comparison Study of Clinicopathologic Characteristics of
Southern California Asian American Non-small Cell Lung
Cancer (NSCLC) Patients by Smoking Status
Sai-Hong Ignatius Ou, MD, PhD,*†‡ Argyrios Ziogas, PhD,†‡ and Jason A. Zell, DO, MPH*†‡
Background: We previously reported that Asian ethnicity is a favor-
able prognostic factor for overall survival (OS) in non-small cell lung
cancer (NSCLC) patients independent of smoking status. However,
Asian ethnicity represents a diverse and heterogeneous population. In
this report, we compared the clinicopathologic characteristics of Asian
American NSCLC patient subgroups by smoking status.
Methods: Clinicopathologic characteristics of the five major Asian
American NSCLC patient subgroups diagnosed between 1991 and
2005 from three Southern California counties were analyzed. Prog-
nostic factors for OS were evaluated by Cox multivariate analysis.
Results: One thousand one hundred twenty-four NSCLC patients
were analyzed: Filipino American (37.0%), Vietnamese American
(32.8%), Japanese American (11.8%), Chinese American (11.7%),
and Korean American (6.7%). A total of 25.7% of these patients
were never smokers. With the exception of Japanese American,
most of Asian American were native born. Median age of never
smokers was marginally younger than ever smokers (66 years versus 68
years, respectively, p 0.0507). The proportion of never smokers who
were women was 72.7% and ranged from the lowest among Korean
American women (66.7%) to the highest among Japanese American
women (84.2%). Among female patients, Vietnamese American pa-
tients had the highest proportion of being never smokers (65.5%).
Significantly more never smokers (60.9%) than ever smokers (47.9%)
presented with stage 4 disease. There was no statistical significant
difference in OS between never smokers and ever smokers (11 versus
10 months; p  0.3040). Tumor-related factors (stage and histologic
differentiation) and treatment (surgery and chemotherapy) were inde-
pendent prognostic factors for survival.
Conclusions: We found no statistical significant difference in clinico-
pathologic features or survival outcome between individual Asian
American subgroup when analyzed according to smoking status.
Key Words: Non-small cell lung cancer, Asian American, Filipino
American, Vietnamese American, Chinese American, Japanese
American, Korean American, Never smoker, California Cancer
Registry, Prognostic factors.
(J Thorac Oncol. 2010;5: 158–168)
Although tobacco-related lung cancer mortality is the num-ber 1 cause of cancer death globally, deaths from lung
cancer patients who were never smokers accounts for the
seventh most common cancer cause of death globally.1 Lung
cancer in never smokers is commonly adenocarcinoma his-
tology, predominantly occurs in women, presents with ad-
vanced stage, harbors mutations in the epidermal growth
factor receptor (EGFR) but not K-ras, and possesses different
mutation profiles in the p53 tumor suppressor gene (transver-
sions in smokers and transitions in never smokers).2–4 Lung
cancer in never smokers also responds better to chemotherapy
and has better survival outcome.5–7 There is a remarkable re-
gional variation in the proportion of lung cancer patients who are
never smokers. Never smokers with lung cancer are found in
greater proportion among Asians, especially Asian women.2,3
Lung cancer is the most common cancer cause of mortality for
the five most populous Asian American subgroups (Chinese
American, Vietnamese American, Filipino American, Japanese
American, and Korean American) in the United States.8 Lung
cancer is also the most common cancer cause of mortality for the
same five subgroups in California except for Vietnamese Amer-
ican women.9 We have shown that Asian American ethnicity is
an independent favorable prognostic factor after factoring in
smoking status in a multivariate analysis among non-small cell
lung cancer (NSCLC) patients in Southern California.10 How-
ever, Asian Americans are extremely diverse with respect to
country of origin, socioeconomic status (SES), time since im-
migration, language spoken, religion practiced, and many other
characteristics that affect health outcome. Studies have shown
that different Asian American subgroups in the United States
have different cancer burdens, that individual Asian American
subgroups should be monitored separately, and that presenting
one statistical estimate for Asian Americans does not accurately
depict cancer burden of any different Asian subgroup.8,9 Further-
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more, although Asian American may have lower lung cancer
risk when compared with whites, the lung cancer risk is
different among different Asian American subgroups.11
In 2007, the U.S. census bureau estimated that California
is home to 4.5 million Asian Americans (34% of the total Asian
American population in the United States). In this report, we
describe and compare clinicopathologic characteristics and sur-
vival outcomes of the five most common Asian American
NSCLC patient subgroups (Filipino American, Vietnamese
American, Japanese American, Chinese American, and Korean
American) in three counties of Southern California.
PATIENTS AND METHODS
Population
This is a retrospective data analysis from the Cancer
Surveillance Programs of Orange, San Diego, and Imperial
counties in Southern California databases covering an area
with estimated population of 6.0 million. The five most
populous Asian American NSCLC patients in the three coun-
ties (Filipino Americans, Vietnamese Americans, Japanese
Americans, Chinese Americans, and Korean Americans) who
were diagnosed between 1991 and 2005 and had complete
follow-up data up to December 2007 were included in the
study. Tumor site was abstracted as previously described.12
American Joint Committee on Cancer (AJCC) stage rather
than Surveillance, Epidemiology, and End Results (SEER)
summary stage (local, regional, or distant) was assigned to
individual patients. For the period 1991–2002, AJCC stage
was abstracted from existing AJCC codes and derived from
SEER extent of disease codes where tumor, node, metastasis
data were missing, as done previously.10 For patients diag-
nosed between 2003 and 2005, SEER-AJCC summary stag-
ing was used. Demographic data including age, ethnicity,
gender, marital status, surgery, radiation, and chemotherapy
given during the first course of therapy were abstracted using
SEER codes. Ethnicity data and marital status were obtained
using California Cancer Registry (CCR) codes. Radiation
therapy and surgical techniques were abstracted using SEER
codes. Chemotherapy given during the first course of therapy
was ascertained using CCR codes. The measurement of SES
used in this analysis was a composite measure using CCR and
census data as previously described.12
Smoking status was abstracted using a customized text
mining program in SAS 9.2 (SAS Institute, Inc., Cary, NC)
that examines text files of individual patient records as
previously described.10,13 Patients with any documented his-
tory of smoking were classified as “ever smokers.” Patients
with documentation of no smoking history were classified as
“never smokers.” Patients lacking documented information
on smoking history were excluded from this analysis.
Statistical Analyses
Comparisons of demographic, clinical, and pathologic
variables were made for NSCLC patients, using Pearson 2
statistic for nominal variables and Student t test for continu-
ous variables. Univariate survival rate analyses were esti-
mated using the Kaplan-Meier method, with comparisons
made between groups by the log-rank test. Cox proportional
hazards modeling using time since diagnosis were performed.
All statistical analyses were conducted using SAS 9.2 statis-
tical software (SAS Institute, Inc.). Statistical significance
was assumed for a two-tailed p value less than 0.05.
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (2007-6078).
RESULTS
Characteristic of Asian American NSCLC
Patients
Between 1991 and 2005, a total of 1124 patients from
Southern California were analyzed, comprising the five major
Asian American NSCLC patient subgroups having complete
follow-up data and known smoking status. Two hundred
eighty-nine patients (25.7%) were never smokers. There were
575 patients with unknown smoking status were excluded
from the analysis. The distribution of Asian American sub-
groups among those with unknown smoking status was sim-
ilar to the distribution of Asian American subgroup with
known smoking status reported in this study.
Period of Diagnosis
The proportion of Asian American NSCLC patients who
were never smokers increased significantly with time: 16.5%
(1991–1995), 25.7% (1996–2000), and 31.2% (2001–2005)
(ptrend  0.0001). Among female patients, the proportion of
NSCLC patients who were never smokers also
increased significantly (37.0%, 48.7%, and 59.5%, respectively,
ptrend  0.0009). The proportion of male NSCLC patients who
were never smokers also increased, but the trend was not
significant (9.1%, 11.7%, and 11.9%, respectively, ptrend 
0.3598). The proportion of never smokers within individual
Asian American subgroup by period of diagnosis were plotted in
Figures 1A (all patients), B (male), and C (female). Among
individual Asian American subgroup, the trend of increasing
proportion of never smokers was significant for Vietnamese
American patients as a whole (16.7%, 22.8%, and 39.7%,
respectively, ptrend 0.0001) and for female Vietnamese Amer-
ican patients (40.0%, 46.3%, and 89.1%, respectively, ptrend 
0.0001). On the other hand, the proportion of female Filipino
American NSCLC patients who were never smokers remained
constant throughout the three periods of diagnosis (52.6%,
56.4%, and 54.1%, respectively, ptrend  0.9956).
Age at Diagnosis
The median age of diagnosis of never smokers (66
years) was lower than that of ever smokers (68 years), and the
difference was borderline significant (p  0.0507) (Table 1).
Female never smokers were significantly younger than female
ever smokers (65 versus 69 years, p  0.0111) (Table 1).
Histology
Significantly, more never smokers were diagnosed with
adenocarcinoma (59.2%) than ever smokers (41.8%). Simi-
larly, the proportion of bronchioloalveolar carcinoma diag-
nosed in never smokers was 8.7% compared with 3.4% in
ever smokers. The proportion of squamous cell carcinoma
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was 24.7% in ever smokers to 7.3% in never smokers (Table
1).
Stage at Presentation
Significantly more never smokers (60.9%) presented
with stage 4 NSCLC compared with ever smokers (47.9%,
p  0.0001), and the difference was similar for male (p 
0.0014) and female (p  0.0015) patients (Table 1).
Asian American Subgroups
Filipino American (37.0%), Vietnamese American
(32.8%), Japanese American (11.8%), Chinese American
(11.7%), and Korean American (6.7%) constituted the Asian
American NSCLC patient subgroups. The proportion of
never smokers within individual Asian American subgroup
was 34.3% (Chinese American), 28.5% (Vietnamese Amer-
ican), 24.5% (Filipino American), 24.0% (Korean American),
and 14.3% (Japanese American) (Table 2). The median ages
of diagnosis of never smokers and ever smokers among all
five Asian American subgroups as a whole and by gender
were listed in Table 2.
Gender
There were more male than female NSCLC patients
within each Asian American subgroup except for Japanese
Americans where 62.4% of patients were women (Table
3). Female patients comprised the majority of Asian Amer-
ican NSCLC never smokers and ranged from 66.7% among
Korean American never smokers to 84.2% among Japanese
American never smokers (Table 3). Among female pa-
tients, the proportion of female NSCLC patients who were
never smokers ranged from the lowest (19.3%) among
female Japanese American patients to the highest
(65.5%) among female Vietnamese American patients
(Table 2).
Socioeconomic Status
There was no statistical significant difference in the
distribution of SES between never smokers and ever smokers
as a whole (Table 1) or within each of the five Asian
subgroups by smoking status (Table 3).
FIGURE 1. A, The proportion of never smokers among individual Asian American non-small cell lung cancer (NSCLC) patients by
three periods of diagnosis. B, The proportion of male never smokers among individual Asian American NSCLC patients by three
periods of diagnosis. C, The proportion of female never smokers among individual Asian American NSCLC patients by three periods
of diagnosis.
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TABLE 1. Clinicopathologic Characteristics of Asian American NSCLC Patients by Smoking Status and Gender
Total Male Female
Ever
Smoker
Never
Smoker p
Ever
Smoker
Never
Smoker p
Ever
Smoker
Never
Smoker p
N (%)a 835 (74.3) 289 (25.7) 637 (89.0) 79 (11.0) 198 (48.5) 210 (51.5)
Median age, yr (95% CI) 68 (47–83) 66 (44–86) 0.0507b 68 (47–82) 70 (38–89) 0.4306b 69 (47–85) 65 (44–85) 0.0111b
Median follow-up time, mo
(95% CI)
9 (1–87) 10 (0–71) 0.5994b 8 (0–97) 7 (0–86) 0.3128b 10 (0–65) 11 (1–71) 0.6030b
Period of diagnosis 0.0001 0.5736 0.0035
1991–1995 227 (27.2) 45 (15.6) 181 (28.4) 18 (22.8) 46 (23.2) 27 (12.9)
1996–2000 295 (35.3) 102 (35.3) 218 (34.2) 29 (36.7) 77 (38.9) 73 (34.8)
2001–2005 313 (37.5) 142 (49.1) 238 (37.4) 32 (40.5) 75 (37.9) 110 (52.4)
Age, yr 0.0280 0.0007 0.0280
0–39 5 (2.5) 8 (2.8) 5 (0.8) 4 (5.1) 5 (2.5) 8 (3.8)
40–49 8 (4.0) 21 (10.0) 43 (6.8) 6 (7.6) 8 (4.0) 21 (10.0)
50–59 40 (20.2) 48 (22.9) 103 (16.2) 8 (10.1) 40 (20.2) 48 (22.9)
60–69 47 (23.7) 55 (26.2) 199 (31.2) 20 (25.3) 47 (23.7) 55 (26.2)
70–79 73 (36.9) 49 (23.3) 228 (935.8) 25 (31.7) 73 (36.9) 49 (23.30)
80 25 (12.6) 29 (13.8) 59 (9.3) 16 (20.3) 25 (12.6) 29 (13.8)
Sex 0.0001
Male 637 (76.3) 79 (27.3) — — — —
Female 198 (23.7) 210 (72.7) — — — — — —
Asian American subgroup 0.0029 0.4202 0.0001
Filipino American 314 (37.6) 102 (35.3) 253 (39.70) 28 (35.4) 61 (30.8) 74 (35.2)
Vietnamese American 264 (31.6) 105 (36.3) 224 (35.2) 29 (36.7) 40 (20.2) 76 (36.2)
Japanese American 114 (13.7) 19 (6.6) 47 (7.4) 3 (3.8) 67 (33.8) 16 (7.6)
Chinese American 86 (10.3) 45 (15.6) 67 (10.50) 13 (16.5) 19 (9.6) 32 (15.2)
Korean American 57 (6.8) 18 (6.2) 46 (7.2) 6 (7.6) 11 (5.6) 12 (5.7)
Histology 0.0001 0.0025 0.0001
Adenocarcinoma 349 (41.8) 171 (59.2) 260 (40.8) 48 (60.8) 89 (45.0) 123 (58.6)
BAC 28 (3.4) 25 (8.7) 20 (3.1) 2 (2.5) 8 (4.0) 23 (11.0)
Large cell 50 (6.0) 16 (5.5) 40 (6.3) 8 (10.1) 10 (5.1) 8 (3.8)
Squamous cell 206 (24.7) 21 (7.3) 162 (25.4) 9 (11.4) 44 (2.2) 12 (5.7)
Mixed/NOS/other 202 (24.2) 56 (19.4) 155 (24.3) 12 (15.2) 47 (23.7) 44 (21.0)
Histologic differentiation 0.0012 0.6917 0.0055
Well 28 (3.4) 18 (6.2) 22 (3.5) 1 (1.3) 6 (93.0) 17 (8.1)
Moderately 117 (14.0) 48 (16.6) 83 (13.0) 11 (13.9) 34 (17.2) 37 (17.6)
Poorly 285 (34.1) 76 (26.3) 221 (34.7) 29 (36.7) 64 (32.3) 47 (22.4)
Undifferentiated 42 (5.0) 4 (1.4) 33 (5.2) 2 (2.5) 9 (4.6) 2 (1.0)
Unknown 363 (43.5) 143 (49.5) 178 (43.6) 36 (45.6) 85 (42.9) 107 (51.0)
AJCC stage 0.0004 0.0014 0.0015
Stage 1 80 (9.6) 30 (10.4) 63 (9.9) 5 (6.3) 17 (8.60) 25 (11.9)
Stage 2 38 (4.6) 4 (1.4) 29 (4.6) 2 (2.5) 9 (4.6) 2 (1.0)
Stage 3 194 (23.2) 44 (15.2) 136 (21.4) 9 (11.4) 58 (29.30) 35 (16.7)
Stage 4 400 (47.9) 176 (60.9) 318 (49.9) 59 (74.7) 82 (41.4) 117 (55.7)
Unknown 123 (14.7) 35 (12.1) 91 (14.3) 4 (5.1) 32 (16.2) 31 (14.8)
Socioeconomic status 0.4874 0.3520 0.6875
SES1 (lowest) 96 (11.5) 30 (10.4) 79 (12.4) 6 (7.6) 17 (8.6) 24 (11.4)
SES2 177 (21.2) 56 (19.4) 133 (20.9) 12 (15.2) 44 (22.2) 44 (21.0)
SES3 215 (25.7) 65 (22.5) 170 (26.7) 20 (25.3) 45 (22.7) 45 (21.4)
SES4 187 (22.4) 68 (23.5) 137 (21.5) 23 (29.1) 50 (25.3) 45 (21.4)
SES5 (highest) 146 (17.5) 62 (21.5) 108 (17.0) 14 (17.7) 38 (19.2) 48 (22.9)
Unknown 14 (1.7) 8 (2.8) 10 (1.6) 4 (5.1) 4 (2.0) 4 (1.9)
Marital status 0.1208 0.9974 0.0136
Married 609 (72.9) 194 (67.1) 515 (80.6) 64 (81.0) 94 (47.5) 130 (61.9)
Unmarried 203 (24.3) 88 (30.5) 105 (16.5) 13 (16.5) 98 (49.5) 75 (35.7)
Unknown 23 (2.8) 7 (2.4) 17 (2.7) 2 (92.5) 6 (3.0) 5 (2.4)
(Continued)
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Place of Origin
Most of Filipino American (86.1%), Vietnamese
American (83.7%), Korean American (72.0%), and Chi-
nese American (70.2%) NSCLC patients were born in their
native countries whereas slightly less than half of Japanese
American patients were native born (48.1%). However,
most Japanese American never smokers (57.9%) were still
born in Japan (Table 4). Furthermore, the proportion of
Japanese never smokers was higher among native Japanese
(17.2%) than nonnative Japanese (11.6%) NSCLC patients
(Table 5).
Univariate Survival Analysis
Period of Diagnosis
The median overall survival (OS) improved over time:
9 months (1991–1995), 10 months (1996–2000), and 12
months (2001–2005), and the difference was borderline sta-
tistically significant (p  0.0524).
TABLE 2. Median Age of Diagnosis of Individual Asian American Subgroup
Smoking Status
Never
Smoker
Ever
Smoker p
Never
Smoker
Ever
Smoker p
Never
Smoker
Ever
Smoker p
All (N  416) Male (N  281) Female (N  135)
Filipino American 0.2557 0.4176 0.4019
N (%) 102 (24.5) 314 (75.5) 28 (10.0) 253 (90.0) 74 (54.8) 61 (45.2)
Median age (95% CI) 67 (43–5) 68 (45–84) 70 (38–89) 69 (48–83) 65 (43–85) 67 (42–85)
All (N  369) Male (N  253) Female (N  116)
Vietnamese American 0.6600 0.3625 0.1415
N (%) 105 (28.5) 264 (71.5) 29 (11.5) 224 (88.5) 76 (65.5) 40 (34.5)
Median age (95% CI) 65 (41–86) 67 (45–83) 68 (38–89) 66 (45–82) 64 (44–86) 70 (38–89) 0.1415
All (N  133) Male (N  50) Female (N  83)
Japanese American 0.6294 0.5261 0.5364
N (%) 19 (14.3) 114 (85.7) 3 (6.0) 47 (84.0) 16 (19.3) 67 (80.7)
Median age (95% CI) 66 (49–82) 609 (51–83) 74 (71–81) 73 (48–83) 65 (49–82) 67 (54–83)
All (N  131) Male (N  80) Female (N  51)
Chinese American 0.0639 0.5745 0.0141
N (%) 45 (34.4) 86 (65.6) 13 (16.2) 67 (83.8) 32 (62.7) 19 (37.3)
Median age (95% CI) 69 (45–85) 73 (52–83) 69 (45–90) 72 (52–82) 68 (44–85) 76 (52–90)
All (N  75) Male (N  52) Female (N  23)
Korean American 0.4197 0.4474 1.000
N (%) 18 (24.0) 57 (76.0) 6 (11.5) 46 (88.5) 12 (52.2) 11 (47.8)
Median age (95% CI) 57 (39–87) 65 (48–81) 59 (49–86) 63 (48–81) 56 (39–87) 69 (49–76)
TABLE 1. (Continued)
Total Male Female
Ever
Smoker
Never
Smoker p
Ever
Smoker
Never
Smoker p
Ever
Smoker
Never
Smoker p
Surgery 0.8695 0.4018 0.8781
Yes 183 (21.9) 62 (21.5) 139 (21.8) 14 (17.7) 44 (22.2) 48 (22.9)
No 652 (78.1) 227 (78.6) 498 (78.2) 65 (82.3) 154 (77.8) 162 (77.1)
Radiation 0.0067 0.2444 0.1371
Yes 377 (45.2) 104 (36.0) 294 (46.2) 31 (39.2) 83 (41.9) 73 (34.8)
No 458 (54.8) 185 (64.0) 343 (53.9) 48 (60.8) 115 (58.1) 137 (65.2)
Chemotherapy 0.1170 0.1899 0.4685
Yes 310 (37.1) 125 (43.3) 234 (36.7) 37 (46.8) 76 (38.4) 88 (41.9)
No 522 (62.5) 164 (56.8) 400 (62.8) 42 (53.2) 122 (61.6) 122 (58.1)
Unknown 3 (0.4) 0 (0.0) 3 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
a Percentage calculated across the row.
b p value calculated by Wilson two-sample test.
NSCLC, non-small cell lung cancer; BAC, bronchoalveolar carcinoma; AJCC, American Joint Committee on Cancer; SES, socioeconomic status; NOS, not otherwise specified.
Ou et al. Journal of Thoracic Oncology • Volume 5, Number 2, February 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer162
TA
B
LE
3.
C
lin
ic
op
at
ho
lo
gi
c
C
ha
ra
ct
er
is
tic
s
of
In
di
vi
du
al
A
si
an
A
m
er
ic
an
Su
bg
ro
up
by
Sm
ok
in
g
St
at
us
F
ili
pi
no
A
m
er
ic
an
V
ie
tn
am
es
e
A
m
er
ic
an
C
hi
ne
se
A
m
er
ic
an
Ja
pa
ne
se
A
m
er
ic
an
K
or
ea
n
A
m
er
ic
an
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
N
(%
)a
31
4
(7
5.
5)
10
2
(2
4.
5)
26
4
(7
1.
5)
10
5
(2
8.
5)
86
(6
5.
7)
45
(3
4.
3)
11
4
(8
5.
7)
19
(1
4.
3)
57
(7
6.
0)
18
(2
4.
0)
G
en
de
r

0.
00
01

0.
00
01

0.
00
01
0.
03
41
0.
00
01
M
al
e
25
3
(8
0.
6)
28
(2
7.
5)
22
4
(8
4.
9)
29
(2
7.
6)
67
(7
7.
9)
13
(2
8.
9)
47
(4
1.
2)
3
(1
5.
8)
46
(8
0.
7)
6
(3
3.
3)
F
em
al
e
61
(1
9.
4)
74
(7
2.
5)
40
(1
5.
1)
76
(7
2.
4)
19
(2
2.
1)
32
(7
1.
1)
67
(5
8.
8)
16
(8
4.
2)
11
(1
9.
3)
12
(6
6.
7)
A
ge
ca
te
go
ry
,
yr
0.
26
24
0.
22
60
0.
00
67
0.
91
29
0.
03
00
0–
9
5
(1
.6
)
5
(4
.9
)
5
(1
.9
)
5
(4
.8
)
0
(0
.0
)
1
(2
.2
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
1
(5
.6
)
40
–9
18
(5
.7
)
7
(6
.9
)
23
(8
.7
)
11
(1
0.
5)
2
(2
.3
)
6
(1
3.
3)
4
(3
.5
)
1
(5
.3
)
4
(7
.0
)
2
(1
1.
1)
50
–9
56
(1
7.
8)
16
(1
5.
7)
49
(1
8.
6)
19
(1
8.
1)
9
(1
0.
5)
10
(2
2.
2)
18
(1
5.
8)
4
(2
1.
1)
11
(1
9.
3)
7
(3
8.
9)
60
–9
89
(2
8.
3)
32
(3
1.
4)
79
(2
9.
9)
29
(2
7.
6)
19
(2
2.
1)
7
(1
5.
6)
36
(3
1.
6)
5
(2
6.
)
23
(4
0.
4)
2
(1
1.
1)
70
–0
11
6
(3
6.
9)
29
(2
8.
4)
84
(3
1.
8)
25
(2
3.
8)
44
(5
1.
2)
12
(2
6.
7)
43
(3
7.
7)
6
(3
1.
6)
14
(2
4.
6)
2
(1
1.
1)
80

30
(9
.6
)
13
(1
2.
8)
24
(9
.1
)
16
(1
5.
2)
12
(1
4.
0)
9
(2
0.
0)
13
(1
1.
4)
3
(1
5.
8)
5
(8
.8
)
4
(2
2.
2)
H
is
to
lo
gy
0.
00
24
0.
00
32
0.
02
15
0.
00
02
0.
00
1
A
de
no
ca
rc
in
om
a
14
4
(4
5.
9)
57
(5
5.
9)
11
2
(4
2.
4)
60
(5
7.
1)
33
(3
8.
4)
31
(6
8.
9)
44
(3
8.
6)
11
(5
7.
9)
16
(2
8.
1)
12
(6
6.
7)
B
A
C
13
(4
.1
)
12
(1
1.
8)
9
(3
.4
)
7
(6
.7
)
4
(4
.7
)
2
(4
.4
)
2
(1
.8
)
4
(2
1.
1)
0
(0
.0
)
0
(0
.0
)
L
ar
ge
ce
ll
ca
rc
in
om
a
21
(6
.7
)
4
(3
.9
)
13
(4
.9
)
6
(5
.7
)
11
(1
2.
8)
3
(6
.7
)
4
(3
.5
)
1
(5
.3
)
1
(1
.8
)
2
(1
1.
1)
S
qu
am
ou
s
ce
ll
ca
rc
in
om
a
75
(2
3.
9)
11
(1
0.
8)
54
(2
0.
5)
6
(5
.7
)
16
(1
8.
6)
4
(8
.9
)
38
(3
3.
3)
0
(0
.0
)
23
(4
0.
4)
0
(0
.0
)
U
nd
if
fe
re
nt
ia
te
d
61
(1
9.
4)
18
(1
7.
7)
76
(2
8.
8)
26
(2
4.
8)
22
(2
5.
6)
5
(1
1.
1)
26
(2
2.
8)
3
(1
5.
8)
17
(2
9.
8)
4
(2
2.
2)
A
JC
C
st
ag
e
0.
08
57
0.
34
93
0.
11
41
0.
69
73
0.
24
62
S
ta
ge
1
27
(8
.6
)
11
(1
0.
8)
26
(9
.9
)
11
(1
0.
5)
7
(8
.1
)
3
(6
.7
)
16
(1
4.
0)
3
(1
5.
8)
4
(7
0)
2
(1
1.
1)
S
ta
ge
2
8
(2
.6
)
2
(2
.0
)
8
(3
.0
)
1
(1
.0
)
9
(1
0.
5)
0
(0
.0
)
7
(6
.1
)
1
(5
.3
)
6
(1
0l
5)
0
(0
.0
)
S
ta
ge
3
82
(2
6.
1)
13
(1
2.
8)
58
(2
2.
0)
18
(1
7.
1)
18
(2
0.
9)
8
(1
7.
8)
29
(2
5.
4)
3
(1
5.
8)
7
(1
2.
3)
2
(1
1.
1)
S
ta
ge
4
15
6
(4
9.
7)
60
(5
8.
8)
13
7
(5
1.
9)
65
(6
1.
9)
37
(4
3.
0)
28
(6
2.
2)
42
(3
6.
8)
10
(5
2.
6)
28
(4
9.
1)
13
(7
2.
2)
U
nk
no
w
n
41
(1
3.
1)
16
(1
5.
7)
35
(1
3.
3)
10
(9
.5
)
15
(1
7.
4)
6
(1
3.
3)
20
(1
7.
5)
2
(1
0.
5)
12
(2
1.
1)
1
(5
.6
)
H
is
to
lo
gi
c
di
ff
er
en
tia
tio
n
0.
01
40
0.
75
63
0.
55
95
0.
03
05
0.
76
85
W
el
l
8
(2
.6
)
8
(7
.8
)
6
(2
.3
)
3
(2
.9
)
6
(7
.0
)
3
(6
.7
)
4
(3
.5
)
3
(1
5.
8)
4
(7
.0
)
1
(5
.6
)
M
od
er
at
el
y
38
(1
2.
1)
18
(1
7.
7)
42
(1
5.
9)
15
(1
4.
3)
10
(1
1.
6)
8
(1
7.
8)
17
(1
4.
9)
4
(2
1.
1)
10
(1
7.
5)
3
(1
6.
7)
P
oo
rl
y
11
9
(3
7.
9)
30
(2
9.
4)
71
(2
6.
9)
24
(2
2.
9)
27
(3
1.
4)
14
(3
1.
1)
44
(3
8.
6)
2
(1
0.
5)
24
(4
2.
1)
6
(3
3.
3)
U
nd
if
fe
re
nt
ia
te
d
17
(5
.4
)
1
(1
.0
)
9
(3
.4
)
2
(1
.9
)
8
(9
.3
)
1
(2
.2
)
6
(5
.3
)
0
(0
.0
)
2
(3
.5
)
0
(0
.0
)
U
nk
no
w
n
13
2
(4
2.
0)
45
(4
4.
1)
13
6
(5
1.
5)
61
(5
8.
1)
35
(4
0.
7)
19
(4
2.
2)
43
(3
7.
7)
10
(5
2.
6)
17
(2
9.
8)
8
(4
4.
4)
S
oc
io
ec
on
om
ic
st
at
us
0.
98
32
0.
28
99
0.
76
66
0.
69
11
0.
86
72
S
E
S
1
44
(1
4.
0)
12
(1
1.
8)
41
(1
5.
5)
16
(1
5.
2)
5
(5
.8
)
1
(2
.2
)
4
(3
.5
)
1
(5
.3
)
2
(3
.5
)
0
(0
.0
)
S
E
S
2
56
(1
7.
8)
19
(1
8.
6)
80
(3
0.
3)
27
(2
5.
7)
8
(9
.3
)
3
(6
.7
)
18
(1
5.
8)
2
(1
0.
5)
15
(2
6.
3)
5
(2
7.
8)
S
E
S
3
89
(2
8.
3)
28
(2
8.
3)
73
(2
7.
7)
22
(2
1.
0)
19
(2
2.
1)
8
(1
7.
8)
26
(2
2.
8)
5
(2
6.
3)
8
(1
4.
0)
2
(1
1.
8)
S
E
S
4
76
(2
4.
2)
26
(2
6.
3)
42
(1
5.
9)
24
(2
2.
9)
16
(1
8.
6)
9
(2
0.
0)
34
(2
9.
8)
3
(1
5.
8)
19
(3
3.
3)
6
(3
3.
3)
S
E
S
5
45
(1
4.
3)
14
(1
4.
1)
27
(1
0.
2)
15
(1
4.
4)
35
(4
0.
7)
22
(4
8.
9)
31
(2
7.
2)
7
(3
6.
8)
8
(1
4.
0)
4
(2
2.
2)
U
nk
no
w
n
4
(1
.3
)
3
(2
.9
)
1
(0
.4
)
1
(1
.0
)
3
(3
.5
)
2
(4
.4
)
1
(0
.9
)
1
(5
.3
)
5
(8
.8
)
1
(5
.6
) (C
on
ti
nu
ed
)
Journal of Thoracic Oncology • Volume 5, Number 2, February 2010 Clinicopathologic Characteristics of NSCLC Patients
Copyright © 2010 by the International Association for the Study of Lung Cancer 163
TA
B
LE
3.
(C
on
tin
ue
d) Fi
lip
in
o
A
m
er
ic
an
V
ie
tn
am
es
e
A
m
er
ic
an
C
hi
ne
se
A
m
er
ic
an
Ja
pa
ne
se
A
m
er
ic
an
K
or
ea
n
A
m
er
ic
an
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
E
ve
r
Sm
ok
er
N
ev
er
Sm
ok
er
p
M
ar
it
al
st
at
us
0.
34
92
0.
55
26
0.
40
29
0.
05
90
0.
82
02
M
ar
ri
ed
24
1
(7
6.
8)
72
(7
0.
6)
18
6
(7
0.
5)
69
(6
5.
7)
55
(6
4.
0)
28
(6
2.
2)
76
(6
6.
7)
9
(4
7.
4)
51
(8
9.
5)
16
(8
8.
9)
U
nm
ar
ri
ed
68
(2
1.
7)
29
(2
8.
4)
66
(2
5.
0)
32
(3
0.
5)
28
(3
2.
6)
17
(3
7.
8)
36
(3
1.
6)
8
(4
2.
1)
5
(8
.7
)
2
(1
1.
1)
U
nk
no
w
n
5
(1
.6
)
1
(1
.0
)
12
(4
.5
)
4
(3
.8
)
3
(2
.5
)
0
(0
.0
)
2
(1
.8
)
2
(1
0.
5)
1
(1
.8
)
0
(0
.0
)
S
ur
ge
ry
0.
74
34
0.
66
49
0.
98
65
0.
51
62
0.
53
12
Y
es
66
(2
1.
0)
23
(2
2.
5)
53
(2
0.
1)
19
(1
8.
1)
19
(2
2.
1)
10
(2
2.
2)
28
(2
4.
6)
6
(3
1.
6)
17
(2
9.
8)
4
(2
2.
2)
N
o
24
8
(7
9.
0)
79
(7
7.
5)
21
1
(9
.9
)
86
(8
1.
9)
67
(7
7.
9)
35
(7
7.
8)
86
(7
5.
4)
13
(6
8.
4)
40
(7
0.
2)
14
(7
7.
8)
R
ad
ia
ti
on
0.
00
30
0.
19
48
0.
10
10
0.
10
34
0.
40
45
Y
es
14
8
(4
7.
1)
31
(3
0.
4)
11
5
(4
3.
6)
38
(3
6.
2)
33
(3
8.
4)
24
(5
3.
3)
59
(5
1.
8)
6
(3
1.
6)
22
(3
8.
6)
5
(2
7.
8)
N
o
16
6
(5
2.
9)
71
(6
9.
6)
14
9
(5
6.
4)
67
(6
3.
8)
53
(6
1.
6)
21
(4
6.
7)
55
(4
8.
2)
13
(6
8.
4)
35
(6
1.
4)
13
(7
2.
2)
C
he
m
ot
he
ra
py
0.
84
96
0.
17
83
0.
00
07
0.
83
18
0.
91
21
Y
es
12
0
(3
8.
2)
39
(3
8.
2)
91
(3
4.
5)
46
(4
3.
8)
19
(2
2.
1)
23
(5
1.
1)
57
(5
0.
0)
10
(5
2.
6)
23
(4
0.
4)
7
(3
8.
9)
N
o
19
3
(6
1.
5)
63
(6
1.
8)
17
1
(6
4.
8)
59
(5
6.
2)
67
(7
7.
9)
22
(4
8.
9)
57
(5
0.
0)
9
(4
7.
4)
34
(5
9.
7)
11
(6
1.
1)
U
nk
no
w
n
1
(0
.3
)
0
(0
.0
)
2
(0
.8
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
a
P
er
ce
nt
ag
e
ca
lc
ul
at
ed
ac
ro
ss
ro
w
.
B
A
C
,
br
on
ch
oa
lv
eo
la
r
ca
rc
in
om
a;
A
JC
C
,
A
m
er
ic
an
Jo
in
t
C
om
m
it
te
e
on
C
an
ce
r;
S
E
S
,
so
ci
oe
co
no
m
ic
st
at
us
.
TA
B
LE
4.
Pl
ac
e
of
O
rig
in
of
th
e
In
di
vi
du
al
A
si
an
A
m
er
ic
an
Su
bg
ro
up
F
ili
pi
no
A
m
er
ic
an
V
ie
tn
am
es
e
A
m
er
ic
an
C
hi
ne
se
A
m
er
ic
an
Ja
pa
ne
se
A
m
er
ic
an
K
or
ea
n
A
m
er
ic
an
A
ll
N
ev
er
Sm
ok
er
E
ve
r
Sm
ok
er
A
ll
N
ev
er
Sm
ok
er
E
ve
r
Sm
ok
er
A
ll
N
ev
er
Sm
ok
er
E
ve
r
Sm
ok
er
A
ll
N
ev
er
Sm
ok
er
E
ve
r
Sm
ok
er
A
ll
N
ev
er
Sm
ok
er
E
ve
r
Sm
ok
er
N
41
6
10
2
31
4
36
9
10
5
26
4
13
1
45
86
13
3
19
11
4
75
18
57
N
at
iv
e
bo
rn
Y
es
(%
)
35
8
(8
6.
1)
90
(8
8.
2)
26
8
(8
5.
4)
30
9
(8
3.
7)
92
(8
7.
6)
21
7
(8
2.
2)
92
(7
0.
2)
33
(7
3.
3)
59
(6
8.
6)
64
(4
8.
1)
11
(5
7.
9)
53
(4
6.
5)
54
(7
2.
0)
12
(6
6.
7)
42
(7
3.
7)
N
o
(%
)
58
(1
3.
9)
12
(1
1.
8)
46
(1
4.
6)
60
(1
6.
3)
13
(1
2.
4)
47
(1
7.
8)
39
(2
9.
8)
12
(2
6.
7)
27
(3
1.
4)
69
(5
1.
9)
8
(4
2.
1)
61
(5
3.
5)
21
(2
8.
0)
6
(3
3.
3)
15
(2
6.
3)
Ou et al. Journal of Thoracic Oncology • Volume 5, Number 2, February 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer164
Gender
Among never smokers, female patients had statistically
significant improved OS compared with male patients (12
months versus 7 months; p  0.0258). Among ever smokers,
OS differences between female patients (11 months) and
male patients (9 months) were not statistically significant
(p  0.6621).
Smoking Status
No statistically significant differences were observed
between never smokers (11 months) and ever smokers (10
months) (p  0.3040). Within individual Asian American
subgroup, the median OS of Filipino American never
smokers and ever smokers were 10 months and 9 months,
respectively (p  0.7004). For Vietnamese American, the
corresponding median OS for never smokers and ever
smokers were10 months and 7 months, respectively (p 
0.3180); for Japanese American, the corresponding median
OS for never smokers and ever smokers were 16 months
and 12 months, respectively (p  0.7352); for Chinese
American, the corresponding median OS were 12 months
and 10 months, respectively (p  0.3446); and finally, the
corresponding median OS for Korean American never
smokers and ever smokers were 12 months and 13 months,
respectively (p  0.5817).
Ethnicity
There was no statistically significant difference in OS
among the five Asian American subgroups overall (p 
0.1258), among ever smokers (p 0.1131), and among never
smokers (p  0.8663).
Chemotherapy
For stage 4 NSCLC patients, chemotherapy signifi-
cantly improved OS for both ever smokers (8 months with
chemotherapy versus 3 months without chemotherapy; p 
0.0001) and never smokers (11 months versus 3 months,
respectively; p  0.0036) (Figures 2A, B).
Multivariate Survival Analysis
We performed Cox proportional hazards analysis to iden-
tify potential independent prognostic factors. Cox proportional
hazards analysis identified early AJCC stage, well-differentiated
tumor, surgery (versus no surgery, hazard ratio  0.0342, 95%
confidence interval: 0.270–0.432; p 0.001), and chemother-
apy (versus no chemotherapy, hazard ratio  0.595, 95%
confidence interval: 0.511–0.692; p  0.0001) were favor-
able independent prognostic factors after accounting for
age, gender, smoking status, Asian American subgroup,
histology, period of diagnosis, SES, marital status, and
radiation (Table 6).
DISCUSSION
In this report, we provided further analysis of the
clinicopathologic characteristics for the five major Asian
American subgroups that constitute the majority of Asians in
our study, which demonstrated that Asian ethnicity is an
independent favorable prognostic factor for OS in NSCLC.10
Clinicopathologic characteristics common to NSCLC patients
who are never smokers were observed among all Asian
American never smokers subgroups (younger age, predomi-
nance of female gender, adenocarcinoma and bronchioloal-
veolar carcinoma histologies, and advanced disease).
FIGURE 2. A, Kaplan-Meier survival curves of stage 4 ever
smokers with or without chemotherapy. B, Kaplan-Meier sur-
vival curves of stage 4 never smokers with or without che-
motherapy.
TABLE 5. Comparison of Native Versus Nonnative Japanese
American NSCLC Patients
Ever Smoker (%)a Never Smoker (%)a
Nativeb
All (N  64) 53 (82.8) 11 (17.2)
Male (N  11) 11 (100.0) 0 (0.0)
Female (N  53) 42 (79.3) 11 (20.8)
Nonnativeb
All (N  69) 61 (88.4) 8 (11.6)
Male (N  39) 36 (92.3) 3 (7.7)
Female (N  30) 25 (83.3) 5 (16.7)
a Percentage calculated across the row.
b Native, born in Japan; nonnative, not born in Japan.
Journal of Thoracic Oncology • Volume 5, Number 2, February 2010 Clinicopathologic Characteristics of NSCLC Patients
Copyright © 2010 by the International Association for the Study of Lung Cancer 165
With the exception of Japanese American patients
(48.1%), the other four Asian American subgroup of patients
were predominately native (born in their respective coun-
tries). Filipino American and Vietnamese American patients
made up 70% of Asian American patients in this study.
Although lung cancer is the most common cancer and most
common cancer cause of mortality in Philippines,14 there is
limited literature about lung cancer patients who were never
smokers in Philippines. We found that the majority of Fili-
pino American female NSCLC patients were never smokers,
and this proportion had been relatively constant during the 15
years of study period. The epidemiologic profile of Filipino
American patients in this report may reflect the profile of lung
cancer patients in Philippines. Similarly, in Vietnam, lung
cancer is the most common cancer in men,15 but the epide-
miologic profile and survival outcome of lung cancer patients
is again not well described. We observed that Vietnamese
American female NSCLC patients had the highest proportion
of never smokers among the five Asian American female
subgroups, and this proportion had been increasing consis-
tently over time (Figure 2C). In particular, the trend was
statistically significant for Vietnamese American female pa-
tients reaching 89.1% (ptrend 0.0001) during the 2001–2005
period.
Although the median age of Asian American never
smokers as a group was marginally younger than ever smok-
ers (p  0.0507), we did not find a statistically significant
difference in the median age of never smokers when com-
pared with ever smokers among individual Asian American
subgroups. This is likely as a result of the limited number of
patients included in the study.
Similar to our previous report (Figure 4),10 we did not
find statistically significant OS differences between Asian
never smoker and ever smokers as a group or among indi-
vidual Asia American subgroups. This is likely a result of the
limited number of patients in this study as larger studies have
confirmed smoking status as an adverse prognostic factor for
survival in NSCLC.16 In addition, although stage 4 patients
who did not receive chemotherapy had a median OS of 3
months regardless of smoking status, stage 4 patients who
were ever smokers had a 5 months improvement in OS
whereas never smokers had a 8 months improvement in OS
when they received chemotherapy, in agreement with other
retrospective analysis.17 Prospective phase III first-line5,6 and
second-line7 randomized trials of chemotherapy treatment in
advanced NSCLC have also shown that never smokers had
better median OS than ever smokers. For example, the re-
cently presented Iressa Pan-Asia Study trial, which enrolled
Asian never smokers in first-line treatment of NSCLC, re-
ported a median survival of 17 months for never smokers who
received carboplatin and paclitaxel combination chemother-
apy, which is much higher than historical median OS for
NSCLC patients (the majority were ever smokers) in first-line
treatment trials.6 This is likely as a result of combination of
fewer genetic alterations and/or activation of a specific sig-
naling pathway in the tumors of never smokers2,18 and fewer
comorbidities and better performance status in never smokers
(Kawaguchi T, et al., submitted for publication). Never smok-
TABLE 6. Cox Proportional Hazards Model for OS
OS
HR (95% CI) p
Smoking status 0.5285
Ever smoker 1.000
Never smoker 0.943 (0.787–1.131)
Gender 0.7666
Male 1.000
Female 0.975 (0.823–1.154)
AJCC stagea
1 1.000
2 2.160 (1.385–3.368) 0.0007
3 2.177 (1.574–3.010) 0.0001
4 3.527 (2.599–4.787) 0.0001
Age 1.002 (0.996–1.008) 0.5477
Asian American subgroup
Filipino American 1.000
Vietnamese American 1.073 (0.915–1.259) 0.3869
Japanese American 0.947 (0.751–1.195) 0.6468
Chinese American 1.076 (0.854–1.356) 0.5339
Korean American 0.740 (0.549–0.997) 0.0480
Histology
Adenocarcinoma 1.000
BAC 0.874 (0.590–1.295) 0.5025
Squamous cell carcinoma 1.043 (0.870–1.250) 0.6497
Large cell carcinoma 1.302 (0.958–1.770) 0.0918
Undifferentiated/other/mixed 0.957 (0.803–1.140) 0.6195
Histologic gradea
Well differentiated 1.000
Moderately differentiated 1.262 (0.805–1.978) 0.3110
Poor differentiated 1.540 (1.003–2.363) 0.0482
Undifferentiated 1.470 (0.853–2.534) 0.1652
Period of diagnosis
1991–1995 1.000
1996–2000 0.890 (0.750–1.056) 0.1818
2001–2005 0.842 (0.701–1.013) 0.0678
Socioeconomic status 0.961 (0.910–1.015) 0.1539
Marital statusa 0.4159
Married 1.000
Unmarriedb 0.935 (0.795–1.100)
Surgery 0.0001
No 1.000
Yes 0.342 (0.270–0.432)
Radiation 0.8854
No 1.000
Yes 0.990 (0.859–1.141)
Chemotherapya 0.0001
No 1.000
Yes 0.595 (0.511–0.692)
a Unknown included in the Cox proportional hazards analysis but not shown.
b Unmarried  single, separated, divorced, and widowed.
c Others included in the Cox proportional hazards model analysis but not shown.
OS, overall survival; AJCC, American Joint Committee on Cancer; HR, hazard
ratio; CI, confidence interval; BAC, bronchoalveolar carcinoma.
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ers had a high proportion of EGFR mutations that generally
carries a better prognosis.19,20 Given that the majority of and
significantly more never smokers with NSCLC presented
with stage 4 disease and the better prognosis of these patients,
it is imperative that these patients to be offered treatment.
The Cox proportional hazards analysis identified tu-
mor-related factor (stage of diagnosis and histologic differ-
entiation) and treatment-related factors (chemotherapy and
surgery) as independent prognostic factors for OS. The non-
significance of other well-known prognostic factors such as
age, gender, and smoking status by multivariate analysis was
likely as a result of low statistical power from the limited
sample size. Although Korean American ethnicity was found to
be a marginally significant favorable prognostic factor when
compared with Filipino American, currently there is no biologic
basis to account for this observation. In addition, given the
limited number of patients and in particular Korean American
patients in the Cox analysis in which other known prognostic
factors are age and gender, we caution that this observation
should be considered as hypothesis generating.
The major advantage of this study was our ability to
abstract smoking status from a large population-based data-
base as smoking status is not readily available from the CCR
or the national SEER database. We were able to obtain
smoking status without the need to link to other databases
such as Medicare in which the analysis would be limited to a
specific age group. The results from our method of abstract-
ing smoking data from the regional registry is consistent with
the prevalence of smoking data reported by the California
Health Interview Survey, which showed within the general
Asian American population Vietnamese women had the high-
est proportion of nonsmokers whereas Japanese women had
the lowest proportion of nonsmokers.21 In this study, Viet-
namese female NSCLC patients had the highest proportion of
never smokers (65.5%) whereas Japanese female NSCLC
patients had the lowest proportion of never smokers (19.3%)
(Table 2). Another advantage of this study was that we
assigned AJCC stage to individual patients rather than as-
signing patients to the SEER summary staging system of
local, regional, and distant disease. The use of the AJCC
staging system provided a more accurate and relevant clinical
synopsis of the patients especially such as initial stage at
presentation and the benefits of chemotherapy in stage 4
patients.
The major limitation of the study was the limited
patient size. As such, we did not observe statistical significant
differences among individual Asian American subgroup ac-
cording to smoking status. Another limitation of the study
was that environmental tobacco smoke exposure was not
recorded in the cancer registry. However, the genetic profile
of never smoker regardless of second-hand exposure is dif-
ferent from ever smokers in terms of the frequency of EGFR
and K-ras mutations2 or the presence of EML4-ALK translo-
cation.18 Although most of the Asian American were born in
their respective countries and this study may provide a
synopsis of the clinicopathologic characteristics of never
smokers with NSCLC especially Filipino Americans and
Vietnamese Americans, we caution there may be “selection
bias” as the Asian Americans that immigrated to the United
States may be different than the general population in the
native homeland and acculturation22 since time from emigra-
tion. On the other hand, Japanese Americans were eventually
split between native and nonnative. There seemed to be a
trend that a higher proportion of never smokers among native
compared to nonnative Japanese American patients. Al-
though the number of Japanese American patients analyzed
was certainly limited, the data suggest an environmental
contribution to the etiology of never smokers. A comparison
study with adequate sample size aimed at describing the
difference in the clinicopathologic features between native
and nonnative Asian American may provide more clues to the
etiology of the high proportion of never smokers in Asia.
Our study represents the largest population-based anal-
ysis of NSCLC outcomes specifically related to Asian Amer-
ican subgroups while accounting for smoking status. How-
ever, in this analysis no major statistically significant
clinicopathologic differences were observed among Asian
American NSCLC subgroups. Our observational study was
not designed to detect small differences across the various
Asian American NSCLC subgroups, thus one cannot exclude
the possibility of small differences because of limited sample
size and power. For future clinical trial development, it is
likely more appropriate to account for molecular tumor char-
acteristics such as the presence of the EGFR mutations6 rather
than individual Asian American subgroup.
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